Hims & Hers Health (NYSE: HIMS) stock labored mightily on Wednesday, but in the end, it couldn't top the benchmark S&P 500 ...

Telehealth platform Hims & Hers Health, Inc. (HIMS), which connects consumers to healthcare professionals, is at a crossroads ...

Shares of Hims & Hers closed 5.1% higher after the company said it will expand its weight-loss offerings with branded ...

Shares of Hims & Hers Health ( HIMS 5.01%) surged on Tuesday, closing the session up 5.25% after having been up by as much as ...

Eli Lilly quickly disassociated itself from Hims & Hers after the telehealth company said it was selling the pharmaceutical ...

Investors worry patients won’t make that price leap and that Hims, which has built its business on affordable healthcare, ...

The telehealth-consultation platform said it plans to continue expanding its weight loss offerings.

Zepbound, Mounjaro and liraglutide are part of the class of weight loss medications called GLP-1s, which have exploded in ...

Shares of the health and wellness platform operator skyrocketed more than 670% between Jan. 1, 2024, and Feb. 19, 2025.

Hims & Hers (HIMS) is down -5.0%, or -$1.55 to $29.50.Don't Miss Our End of Quarter Offers: Discover the latest stocks recommended by top ...

Hims & Hers Health shares jumped Tuesday as the company added Eli Lilly’s weight-loss drug Zepbound and diabetes treatment ...

Hims & Hers Health (NYSE:HIMS) stock gains as the company adds Eli Lilly's (LLY) weight loss therapy tirzepatide & generic ...